M&A activity is surging. Donald Trump's penchant for deregulation is boosting optimism. This exchange-traded fund gives investors broad exposure to biotech investments. 10 stocks we like better than ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

The State Street SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market. For a ...

FBT returned 29% over the past year and gained 5.4% in the first week of 2026. Federal Reserve officials forecast another 150 basis points of rate cuts in 2026. Healthcare stocks trade at some of the ...

Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative ...

Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index return. FDA drug approvals often trigger 20% to 50% single-day stock jumps that LABU’s ...